



Prof. Raphael Mechoulam joins the advisory board of Therapix Biosciences

Prof. Mechoulam, the “father of medical cannabis” is one of the industry’s pioneers, and was the first to describe the “entourage effect” which serves as basis for one of the Company’s technologies

Therapix Biosciences announces the appointment of Prof. Raphael Mechoulam as member of the Company’s scientific advisory board, further to the decision to focus the Company’s business strategy on development of drugs based on cannabinoid molecules.

Prof. Raphael Mechoulam is a Professor Emeritus of the Department of Natural Products of the School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem, and a member of the Israel Academy of Sciences and Humanities. He is a recipient of the Israel Prize in Exact Sciences - Chemistry, known for his work in identifying the main active compound in the cannabis plant, the THC, and is considered a world-renowned expert. Prof. Mechoulam began his work in this field at the beginning of the sixties and was the first person to synthesize THC.

As part of the proliferous research conducted by Prof. Mechoulam throughout the years in the field, he published his discovery of the “entourage effect” in 1998, currently serving as basis for one of the technologies underlying the new drug developed by the Company for treating Tourette’s syndrome. The entourage technology is based on the principle of integration of cannabinoid substances or cannabinoid analogs with certain drugs in order to improve their efficacy in treating various medical indications. The technology refers to the phenomena of synergy among such substances which are combined in varied dosages for the purpose of improving treatment, in a manner that will also allow reducing the drug dosages known to be active, thus improving the drug’s safety profile.

Prof. Mechoulam is joining the advisory board members currently holding office, together with Dr. Yafit Stark, as new members of the Company’s advisory board.

Dr. Stark holds a PhD in Pathology and a Post-Doctorate in Immuno-Histopathology. In recent years, Dr. Stark served as Vice President, Chief Clinical Officer of the R&D Division at Teva Pharmaceutical Industries Ltd. and as Vice President, Chief Global Clinical Advisor of the R&D Division at Teva Pharmaceutical Industries Ltd.